Biliary Atresia: Long-term Study of Odevixibat

We are studying the long-term effects of odevixibat in children with biliary atresia to see if it helps improve liver health and overall growth. The trial also looks at the safety of this treatment over time.

>2 years 6-10 visits Confirmation phase (III)Post-Trial Drug Access No Placebo Cost Reimbursement Partially Remote Investigational Medicines OralHepatologyPediatrics

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Odevixibat

Odevixibat is a substance that reduces bile acid absorption to relieve severe itching in certain inherited liver disorders.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

A4250

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Universitair Ziekenhuis Gent

Pediatric Gastro-Enterology Department

Ledeberg, Belgium

Hospices Civils De Lyon

Department of Paediatric Hepatology Gastroenterology and Nutrition

Bron, France

Assistance Publique Hopitaux De Paris

Pediatric Hepatology and Liver Transplantation Department

Croulebarbe, France

Sponsor: Ipsen Pharma

Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.